Last reviewed · How we verify
APG-157
APG-157 is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog.
APG-157 is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog. Used for Acute myeloid leukemia (AML).
At a glance
| Generic name | APG-157 |
|---|---|
| Sponsor | Aveta Biomics, Inc. |
| Drug class | GM-CSF analog |
| Target | GM-CSF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by stimulating the production and function of granulocytes and macrophages, which are types of white blood cells that play a crucial role in the immune system. This can help to enhance the body's natural response to infection and inflammation.
Approved indications
- Acute myeloid leukemia (AML)
Common side effects
- Injection site reaction
Key clinical trials
- Safety and Efficacy of APG-157 in Head and Neck Cancer (PHASE2)
- A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia (PHASE2)
- Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab (PHASE1, PHASE2)
- Treatment of Recurrent GBM With APG-157 Via Expanded Access
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |